← All indications
Hamartoma
A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area.
Subtype terms (3)
More specific conditions that are subtypes of Hamartoma in the MeSH hierarchy.
- Hamartoma Syndrome, Multiple
6 drugs (4 approved, 2 experimental)
- Pallister-Hall Syndrome
- Tuberous Sclerosis
16 drugs (11 approved, 5 experimental)
Drugs by status
Phase 4 trials (21)
Phase 3 trials (60)
- vadadustat
- mirvetuximab soravtansine
- gemcitabine
- paclitaxel
- topotecan
- aztreonam
- selenite
- ciprofloxacin
- fluorouracil
- skb264
- rucaparib
- olaparib
- binimetinib
- acetylcarnitine
- saracatinib
- omp-305b83
- aldoxorubicin
- trebananib
- saponin
- capecitabine
- trametinib
- roxadustat
- empagliflozin
- lapatinib
- cediranib
- carboplatin
- human choriogonadotropin alfa
- tamoxifen
- pemtumomab
- polyvalent antigen-klh conjugate vaccine
- +30 more
Phase 2 trials (246)
- Oglufanide
- alvocidib
- sodium thiosulfate
- carotuximab
- pd-0360324
- avb-s6-500
- ef5
- iniparib
- n-(4-hydroxyphenyl)all-trans retinamide
- fludarabine
- ruxolitinib
- sotorasib
- Senaparib
- elu001
- wild-type reovirus
- decitabine
- sintilimab
- e39 peptide vaccine
- berzosertib
- ipatasertib
- tlk286
- vorinostat
- alvac ny eso-1 vaccine
- poly-iclc
- ramucirumab
- hu3s193
- karenitecin
- 131 i-omburtamab
- diphenhydramine
- dpx-survivac
- +216 more
Phase 1 trials (101)
- cdx-301
- apg-1252
- abt-767
- sct-001
- ucb-nk cells
- muc1-klh conjugate vaccine
- cdx-585
- onalespib
- d4064a
- lyl797
- ovarian cancer peptides
- montanide isa51
- calcitriol
- abexinostat
- conatumumab
- autologous ny-eso-1-specific cd8-positive t lymphocytes
- prolactin g129r
- mesothelin car t cells
- nedisertib
- vancomycin
- tumour infiltrating lymphocytes
- coti2
- elimusertib
- sm08502
- qs-21
- ex vivo cd3/cd28-costimulated vaccine-primed peripheral blood autologous t cells
- xmt-1660
- mov19-bbz car t cells
- autologous monocytes
- 23me-00610
- +71 more
Organizations
Organization Involved with Phase 2 Indications (8)
Organization Involved with Other Experimental Indications (1)